Clinical Trial Update: Sunitinib as Second-Line Therapy in Treating Patients With Locally Advanced or Metastatic Transitional Cell Cancer [Phase 2]

View source ↗

Summary

This Phase 2 trial evaluated sunitinib as second-line therapy for locally advanced or metastatic transitional cell cancer of the bladder and upper urinary tract…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bladder Cancer
• Transitional Cell Carcinoma of the Renal Pelvis and Ureter

Drugs mentioned

• Sutent (sunitinib)

Snippet

Sponsor: Institut Curie | Conditions: Bladder Cancer, Transitional Cell Cancer of the Renal Pelvis and Ureter | Phase 2 | Status: COMPLETED